ERBB2 and breast cancer: On August 5, 2022, the Food and Drug Administration approved trastuzumab deruxtecan for adult patients with HER2-low advanced BC who had received prior chemotherapy in a metastatic setting or developed disease recurrence during or within six months of completing adjuvant chemotherapy.